跳至主要内容
临床试验/TCTR20220503004
TCTR20220503004Unknown4 期

The efficacy of combination therapy of metoclopramide and prucalopride versus placebo in reducing gastric residual volume in critically ill patients: A randomized controlled trial

Faculty of Medicine, Prince of Songkla University0 个研究点目标入组 62 人开始时间: 2022年5月3日最近更新:
适应症

试验速览

阶段
4 期
发起方
入组人数
62

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • 1. Patients in medical intensive care units and medical respiratory care units
  • 2. Feeding intolerance, defined as GRV of 250 ml or more
  • 3. Expected to be on tube feeding for at least 5 days (by their primary doctors)

排除标准

  • 1. Receiving prokinetic drugs within the previous 24 hours
  • 2. History of allergy to prucalopride or metoclopramide
  • 3. Gastrointestinal bleeding, obstruction, or perforation
  • 4. Hemodynamic instability at the time of enteral tube feeding initiation, defined as a mean arterial pressure of less than 50 mmHg or escalating doses of vasopressor or inotropic agents required to maintain a MAP value of more than 50 mmHg within 24 hours
  • 5. Undergone major gastrointestinal surgery (laparotomy with part of gastrointestinal tract removed or repaired) within the previous 2 weeks
  • 6. Severe inflammatory conditions of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon, or preexisting chronic diarrheal diseases
  • 7. Underlying of known pheochromocytoma
  • 8. QT prolongation on 12-lead ECG, defined by QTc of more than 440 ms in male and 460 ms in female
  • 9. History of extrapyramidal symptoms
  • 10. Presence of clinical refeeding syndrome
  • 11. On gastrostomy tube
  • 12. Pregnancy

研究者

发起方
Faculty of Medicine, Prince of Songkla University

相似试验